JP7341897B2 - Ｃ３ｂ不活性化ポリペプチド - Google Patents

Ｃ３ｂ不活性化ポリペプチド Download PDF

Info

Publication number
JP7341897B2
JP7341897B2 JP2019567602A JP2019567602A JP7341897B2 JP 7341897 B2 JP7341897 B2 JP 7341897B2 JP 2019567602 A JP2019567602 A JP 2019567602A JP 2019567602 A JP2019567602 A JP 2019567602A JP 7341897 B2 JP7341897 B2 JP 7341897B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
sequence
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527331A5 (https=
JP2020527331A (ja
Inventor
クラーク，サイモン
アンウィン，リチャード
ビショップ，ポール
Original Assignee
コンプリメント・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンプリメント・セラピューティクス・リミテッド filed Critical コンプリメント・セラピューティクス・リミテッド
Publication of JP2020527331A publication Critical patent/JP2020527331A/ja
Publication of JP2020527331A5 publication Critical patent/JP2020527331A5/ja
Priority to JP2023140001A priority Critical patent/JP2023162355A/ja
Application granted granted Critical
Publication of JP7341897B2 publication Critical patent/JP7341897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21045—Complement factor I (3.4.21.45)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019567602A 2017-06-09 2018-06-08 Ｃ３ｂ不活性化ポリペプチド Active JP7341897B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023140001A JP2023162355A (ja) 2017-06-09 2023-08-30 Ｃ３ｂ不活性化ポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1709222.2 2017-06-09
GBGB1709222.2A GB201709222D0 (en) 2017-06-09 2017-06-09 C3b Inactivating Polypeptide
PCT/EP2018/065199 WO2018224663A1 (en) 2017-06-09 2018-06-08 C3b inactivating polypeptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023140001A Division JP2023162355A (ja) 2017-06-09 2023-08-30 Ｃ３ｂ不活性化ポリペプチド

Publications (3)

Publication Number Publication Date
JP2020527331A JP2020527331A (ja) 2020-09-10
JP2020527331A5 JP2020527331A5 (https=) 2021-07-26
JP7341897B2 true JP7341897B2 (ja) 2023-09-11

Family

ID=59358410

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567602A Active JP7341897B2 (ja) 2017-06-09 2018-06-08 Ｃ３ｂ不活性化ポリペプチド
JP2023140001A Pending JP2023162355A (ja) 2017-06-09 2023-08-30 Ｃ３ｂ不活性化ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023140001A Pending JP2023162355A (ja) 2017-06-09 2023-08-30 Ｃ３ｂ不活性化ポリペプチド

Country Status (6)

Country Link
US (2) US20200277360A1 (https=)
EP (1) EP3634985A1 (https=)
JP (2) JP7341897B2 (https=)
CN (1) CN111051337A (https=)
GB (1) GB201709222D0 (https=)
WO (1) WO2018224663A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511030A (ja) * 2018-01-15 2021-05-06 ザ・ユニバーシティ・オブ・マンチェスターＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｎｃｈｅｓｔｅｒ Ｃ３ｂ結合ポリペプチド

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201821082D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
GB202006789D0 (en) 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
EP4214515A1 (en) 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
US20240391976A1 (en) * 2021-11-19 2024-11-28 Ap Biosciences, Inc. Bi-Functional Fusion Proteins to Complement Pathways and Method of Inhibiting Bone Resorption
CN114317562B (zh) * 2022-02-22 2023-06-13 辽宁省农业科学院 普通菜豆镰孢菌枯萎病抗病相关蛋白的编码基因PvEXO70及应用
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535062A (ja) 2013-09-05 2016-11-10 フーダン ユニバーシティ シャンハイ キャンサー センター 特異的補体系を標的化する阻害剤ならびにその調製方法および使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3066699A (en) * 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
GB9930659D0 (en) * 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CA2920293A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
SG11201706840WA (en) * 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535062A (ja) 2013-09-05 2016-11-10 フーダン ユニバーシティ シャンハイ キャンサー センター 特異的補体系を標的化する阻害剤ならびにその調製方法および使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD，2012年，Vol.119, No.26, pp.6307-6316
MolecularImmunology，2015年，Vol.67, pp.137-138, 054
八戸大学紀要，2007年，Vol.34, pp.123-131

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511030A (ja) * 2018-01-15 2021-05-06 ザ・ユニバーシティ・オブ・マンチェスターＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｎｃｈｅｓｔｅｒ Ｃ３ｂ結合ポリペプチド
JP7505980B2 (ja) 2018-01-15 2024-06-25 コンプリメント・セラピューティクス・リミテッド Ｃ３ｂ結合ポリペプチド

Also Published As

Publication number Publication date
CN111051337A (zh) 2020-04-21
JP2023162355A (ja) 2023-11-08
WO2018224663A1 (en) 2018-12-13
EP3634985A1 (en) 2020-04-15
US20240336675A1 (en) 2024-10-10
GB201709222D0 (en) 2017-07-26
US20200277360A1 (en) 2020-09-03
JP2020527331A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7341897B2 (ja) Ｃ３ｂ不活性化ポリペプチド
US11981748B2 (en) Methods for inhibiting angiogenesis in a subject in need thereof
AU2024203142B2 (en) C3b binding polypeptide
Kortvely et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations
CN107638565B (zh) 用于治疗与masp-2依赖性补体活化相关的状况的方法
TR201708554T4 (tr) Masp-2 ye bağlı tamamlayıcı aktivasyon ile ilişkili durumların tedavisi için yöntemler.
JP2003515338A (ja) 補体結合酵素、ｍａｓｐ−３、及びその使用
CN115835880A (zh) Adamts13蛋白质变体及其用途
AU2013201627B2 (en) Methods for treating conditions associated with MASP-2 dependent complement activation
Colineau Investigating the role of C3 in type 2 diabetes onset using mouse models
Kieninger-Gräfitsch et al. EMCHD2019-Abstracts
JP2025063043A (ja) 眼障害の処置方法
AU2015271989A1 (en) Methods for treating conditions associated with MASP-2 dependent complement activation
CN117946240A (zh) 重组补体因子h多肽及其用途
EA051913B1 (ru) Способы ингибирования ангиогенеза у пациента
EA045598B1 (ru) Способы ингибирования ангиогенеза у пациента

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220624

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230830

R150 Certificate of patent or registration of utility model

Ref document number: 7341897

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150